Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.
Saved in:
| Title: | Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. |
|---|---|
| Authors: | Seshadri C; Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Seattle Tuberculosis Research Advancement Center, Seattle, WA, USA. Electronic address: seshadri@uw.edu., Flynn JL; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Maiello P; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Schnappinger D; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA., Wilkinson RJ; Wellcome Discovery Research Platform in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, South Africa; Department of Infectious Diseases, Imperial College London, London, UK; Francis Crick Institute, London, UK., Gordon SB; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Mwandumba HC; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Jambo KC; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Hoft DF; Division of Infectious Diseases, Allergy & Immunology, Center for Vaccine Development, and Department of Molecular Microbiology & Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA., Rubin EJ; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Jamrozik E; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia; Ethox and Pandemic Sciences Institute, University of Oxford, Oxford, UK., Fortune SM; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. |
| Source: | The Lancet. Microbe [Lancet Microbe] 2026 Mar; Vol. 7 (3), pp. 101278. Date of Electronic Publication: 2026 Jan 23. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41587559 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Seshadri+C%22">Seshadri C</searchLink>; Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Seattle Tuberculosis Research Advancement Center, Seattle, WA, USA. Electronic address: seshadri@uw.edu.<br /><searchLink fieldCode="AU" term="%22Flynn+JL%22">Flynn JL</searchLink>; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Maiello+P%22">Maiello P</searchLink>; Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Schnappinger+D%22">Schnappinger D</searchLink>; Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wilkinson+RJ%22">Wilkinson RJ</searchLink>; Wellcome Discovery Research Platform in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, South Africa; Department of Infectious Diseases, Imperial College London, London, UK; Francis Crick Institute, London, UK.<br /><searchLink fieldCode="AU" term="%22Gordon+SB%22">Gordon SB</searchLink>; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.<br /><searchLink fieldCode="AU" term="%22Mwandumba+HC%22">Mwandumba HC</searchLink>; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.<br /><searchLink fieldCode="AU" term="%22Jambo+KC%22">Jambo KC</searchLink>; Malawi-Liverpool-Wellcome Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.<br /><searchLink fieldCode="AU" term="%22Hoft+DF%22">Hoft DF</searchLink>; Division of Infectious Diseases, Allergy & Immunology, Center for Vaccine Development, and Department of Molecular Microbiology & Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Rubin+EJ%22">Rubin EJ</searchLink>; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Jamrozik+E%22">Jamrozik E</searchLink>; Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia; Ethox and Pandemic Sciences Institute, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Fortune+SM%22">Fortune SM</searchLink>; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kublin+JG%22">Kublin JG</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101769019%22">The Lancet. Microbe</searchLink> [Lancet Microbe] 2026 Mar; Vol. 7 (3), pp. 101278. <i>Date of Electronic Publication: </i>2026 Jan 23. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101769019 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-5247 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226665247%22">26665247 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Microbe <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41587559 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.lanmic.2025.101278 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 101278 Titles: – TitleFull: Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Seshadri C – PersonEntity: Name: NameFull: Flynn JL – PersonEntity: Name: NameFull: Maiello P – PersonEntity: Name: NameFull: Schnappinger D – PersonEntity: Name: NameFull: Wilkinson RJ – PersonEntity: Name: NameFull: Gordon SB – PersonEntity: Name: NameFull: Mwandumba HC – PersonEntity: Name: NameFull: Jambo KC – PersonEntity: Name: NameFull: Hoft DF – PersonEntity: Name: NameFull: Rubin EJ – PersonEntity: Name: NameFull: Jamrozik E – PersonEntity: Name: NameFull: Fortune SM – PersonEntity: Name: NameFull: Kublin JG IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2026 Mar Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2666-5247 Numbering: – Type: volume Value: 7 – Type: issue Value: 3 Titles: – TitleFull: The Lancet. Microbe Type: main |
| ResultId | 1 |